Medical Communications, San Francisco, California, USA.
Dermatol Surg. 2012 Jul;38(7 Pt 2):1217-22. doi: 10.1111/j.1524-4725.2012.02477.x.
Initial applications of calcium hydroxylapatite (CaHA) focused on filling lines and wrinkles. Facial volumization with CaHA has not been fully explored.
The purpose of this large scale, prospective, randomized, controlled, multicenter study was to assess CaHA for cheek volumizing, including physician and patient satisfaction.
Subjects ( N = 116) were randomized to an immediate treatment group or to an untreated control group (crossed over at 3 months). Patients received CaHA injections in their cheeks, defined as the malar, submalar, zygoma, preauricular, and infraorbital areas. Assessments of quantitative changes in cheek volume using magnetic resonance imaging analysis, qualitative assessments by masked evaluators, and physician and patient satisfaction analyses were also performed, including overall satisfaction with aesthetic results and likelihood to return for future treatments. Safety was assessed across 12 months.
Mean total treatment volume (107 patients) was 4.7 mL of CaHA. At all points, physicians reported satisfaction of 75% or more, with 92% satisfaction at 12 months. Most patients also reported being satisfied at all time points, with 80% satisfied at 12 months. No serious adverse events occurred.
Midface volumizing with CaHA results in high physician and patient satisfaction up to 12 months from treatment.
最初应用羟基磷灰石钙(CaHA)主要集中在填充线和皱纹上。CaHA 用于面部填充尚未得到充分探索。
本大规模、前瞻性、随机、对照、多中心研究的目的是评估 CaHA 用于脸颊填充的效果,包括医生和患者的满意度。
受试者(N=116)随机分为即刻治疗组或未治疗对照组(3 个月时交叉)。患者在脸颊部位接受 CaHA 注射,包括颧骨、下颌骨、颧骨、耳前和眶下区域。使用磁共振成像分析评估脸颊体积的定量变化,由盲法评估者进行定性评估,以及医生和患者满意度分析,包括对美学效果的总体满意度和再次接受未来治疗的可能性。安全性评估持续 12 个月。
107 例患者的平均总治疗体积为 4.7 毫升 CaHA。在所有时间点,医生报告的满意度均为 75%或更高,12 个月时的满意度为 92%。大多数患者在所有时间点也报告满意,12 个月时的满意度为 80%。未发生严重不良事件。
从治疗开始到 12 个月,CaHA 用于中面部填充可获得较高的医生和患者满意度。